Our site uses cookies to make navigation as functional as possible, including "third party" cookies and "profiling cookies" designed to tailor on-line contents to suit the preferences expressed while surfing the internet. Should you wish to receive more information, or deny your consent to some or all cookies, click here. If you proceed browsing this website, you will be consenting to the use of all cookies.
More info
itaeng
Home
Delafloxacin: Activity against Fastidious Organisms Tested by EUCAST vs CLSI Methodology
asm microbe 2018 Atlanta June 7-11, 2018.
CD205-Shuttle Study: a first in human trial of Men1309/OBT076 an ADC targeting CD205 in solid tumor and NHL
Asco Annual Meeting 2018 Chicago June 1-5,2018
Translational model-based approach to the dose-range selection of an antibody-drug conjugate entering Phase I.
Page twenty-seventy meeting, 29 May-1June, 2018.
The role of MEN1611, a class I PI3-kinase (PI3K) inhibitor, in reprogramming the pro-tumoral inflammatory environment.
AACR Annual Meeting 2018, Chicago April 1-5,2018
MEN1611, a novel a-selective PI3K inhibitor in solid tumors
AACR Annual Meeting 2018, Chicago April 1-5,2018
Page 1 of 2First   Previous   [1]  2  Next   Last   

THERAPEUTIC AREAS

Discover all of Menarini's products marketed in Italy. Read More »

DIAGNOSTICS

 

Advanced Technology

READ MORE »

THE MENARINI GROUP

Discover the leading Italian pharmaceutical company in the world. Read More »

MENARINI PILLS OF ART

Concession granted by Italian Ministry for Cultural Heritage and Activities Read more